1. Scrip
  2. >>Business
  3. >>Strategy

The Better Exit for Private Biotechs: M&A

 
• By Michael Lytton

Does the recent flurry of acquisitions of private biotech companies by pharma companies represent a new and continuing trend? Yes--and a real change in thinking at Big Pharma and among VCs.

Q: Does the recent flurry of acquisitions of private biotech companies by pharma companies represent a new and continuing trend?

A: Yes—the recent acquisitions of Angiosyn Inc. [See Deal], Aton Pharma Inc. [See Deal], Egea Biosciences Inc.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

Actithera Raises $75m To Enter Competitive FAP-Targeting Radioligand Field

 
• By Andrew McConaghie

While companies such as Eli Lilly and Roche have faced setbacks to their fibroblast activation protein-targeting oncology therapies, Actithera believes its radiopharmaceuticals platform will prove more successful.

Concentra Picks Up Cargo In Latest Troubled Biotech Buyout

 
• By Alaric DeArment

The Kevin Tang-led firm will pay $4.38 per share for Cargo, which laid off most of its workforce following the failure of a Phase II CAR-T trial.

Venture Funding Plummets In Q2 As Mega-Rounds Falter

 
• By Mandy Jackson

Evaluate’s second quarter data show that VC rounds of $100m or more totaled $2.36bn, down from $5.25bn in Q2 of 2024. Overall, the Q2 total dropped year-over-year to $4.92bn from $7.95bn.